[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349529-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349529-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-impact-of-combined-oral-contraceptive-use-among-ovarian-cancer-patients-in-addis-ababa-ethiopia-a-cohort-study","Prognostic Impact of Combined Oral Contraceptive Use Among Ovarian Cancer Patients in Addis Ababa, Ethiopia - A Cohort Study","","Ovarian cancer is the third most common gynecological malignancy, and while combined oral contraceptives (COCs) reduce risk of primary disease, their prognostic value after diagnosis remains unclear. A hospital-based retrospective cohort study evaluated 436 ovarian cancer patients in Addis Ababa, Ethiopia (109 COC users, 327 non-users). Kaplan–Meier and log-rank tests assessed overall survival, with mortality incidence density rates and Cox regression for time to death. Prior COC use showed higher 5-year survival (66.18% vs 37.65%) and lower adjusted mortality hazard (AHR=0.37), suggesting improved outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-impact-of-combined-oral-contraceptive-use-among-ovarian-cancer-patients-in-addis-ababa-ethiopia-a-cohort-study/349529/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-impact-of-combined-oral-contraceptive-use-among-ovarian-cancer-patients-in-addis-ababa-ethiopia-a-cohort-study/349529.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s objective regarding combined oral contraceptives (COCs)?","Question",{"text":63,"@type":64},"To evaluate the association between prior COC use and ovarian cancer survival among patients already diagnosed with the disease in oncology centers in Addis Ababa, Ethiopia.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was overall survival compared between COC users and non-users?",{"text":68,"@type":64},"Kaplan–Meier survival curves and the log-rank test were used to assess differences in overall survival between the 109 COC users and 327 non-users.",{"name":70,"@type":61,"acceptedAnswer":71},"What survival and mortality differences were found for prior COC use?",{"text":72,"@type":64},"The 5-year overall survival rate was higher in COC users (66.18%) than non-users (37.65%), and prior COC use was linked to a lower adjusted hazard of mortality (AHR=0.37) after adjustment for confounders.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349529,1790291743,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| Prognostic Impact of Combined Oral Contraceptive Use Among Ovarian Cancer Patients in Addis Ababa, Ethiopia: A Cohort Study\u003Cbr>Abrham Tesfaye Habteyes1 , Fekadeselassie Teferi Mekonen2, and Temesgen Ashagrie Haile3 | Cancer Control Volume 33: 1–12 © The Author(s) 2026 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/10732748261480330](DOI: 10.1177/10732748261480330)\u003Cbr>[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Abstract\u003Cbr>Introduction: Globally, ovarian cancer is the third most common gynecological malignancy, following cervical and uterine cancers. The protective effect of combined oral contraceptive (COC) use against the development of primary ovarian cancer is well-established. However, little is known about the potential prognostic benefit of COC use among patients already diagnosed with ovarian cancer. Therefore, this study aimed to evaluate the association of COC use on ovarian cancer survival in oncology centers in Addis Ababa, Ethiopia. Methods: A hospital-based, retrospective cohort study was conducted among a total of 436 ovarian cancer patients, comprising 109 COC users and 327 non-users. Kaplan–Meier survival curves and the logrank test were used to assess differences in overall survival. The incidence density rate of mortality was calculated for each group. The effect of COC use on time to death following an ovarian cancer diagnosis was estimated using Cox proportional hazards regression, with a significance level of 5% . Results: The mortality incidence density rate among ovarian cancer patients with prior COC use was 5.55 per 1,000 person-years (95% CI: 3.69–8.35), compared with 13.95 per 1,000 person-years (95% CI: 11.89–16.35) among non-users. The 5-year overall survival rate was higher among COC users (66.18%; 95% CI: 53.07– 76.41) than among non-users (37.65%; 95% CI: 31.26–44.01) . The median overall survival time for the cohort was 49.80 months. After adjustment for potential confounders, prior COC use was associated with a lower hazard of mortality compared with non-use (adjusted hazard ratio [AHR] = 0.37; 95% CI: 0.24–0.59). Conclusions: In the present study, prior COCuse was associated with improved overall survival among women diagnosed with ovarian cancer. These findings provide preliminary evidence of a possible prognostic association; however, further studies are needed to confirm these findings and clarify the underlying mechanisms.\u003Cbr>Plain Language Summary\u003Cbr>Ovarian cancer is one of the most common cancers affecting women worldwide. It is known that using combined oral contraceptives (COCs), often called birth control pills, can lower the risk of developing ovarian cancer. However, it has not been clear whether past use of these pills also affects survival after a woman has already been diagnosed with ovarian cancer. This study observed at 436 women diagnosed with ovarian cancer who were treated at oncology centers in Addis Ababa, Ethiopia. Among them, 109 had previously used combined oral contraceptives, while 327 had not. The researchers followed these women for fiveyears to compare survival outcomes between the two groups. The results showed that women who had |  |\n| 1Department of Nursing, College of Health Sciences, Ethiopian Defence University, Bishoftu, Ethiopia 2Department of Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia\u003Cbr>3Menelik II Medical and Health Science College, City Administration of Addis Ababa Health Bureau, Addis Ababa, Ethiopia\u003Cbr>Corresponding author:\u003Cbr>Abrham Tesfaye Habteyes, Department of Nursing, College of Health Sciences, Ethiopian Defence University, Bishoftu, Ayat, Addis Ababa, Ethiopia.\u003Cbr>Email: [abrhamtesfaye95@gmail.com](abrhamtesfaye95@gmail.com) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://c","cbCaidPRkH1OtY6y","https://ap.wps.com/l/cbCaidPRkH1OtY6y","pdf",1537520,12,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions\n## Plain Language Summary\n## Keywords\n## Introduction","[{\"question\":\"What was the study’s objective regarding combined oral contraceptives (COCs)?\",\"answer\":\"To evaluate the association between prior COC use and ovarian cancer survival among patients already diagnosed with the disease in oncology centers in Addis Ababa, Ethiopia.\"},{\"question\":\"How was overall survival compared between COC users and non-users?\",\"answer\":\"Kaplan–Meier survival curves and the log-rank test were used to assess differences in overall survival between the 109 COC users and 327 non-users.\"},{\"question\":\"What survival and mortality differences were found for prior COC use?\",\"answer\":\"The 5-year overall survival rate was higher in COC users (66.18%) than non-users (37.65%), and prior COC use was linked to a lower adjusted hazard of mortality (AHR=0.37) after adjustment for confounders.\"}]","Prognostic Impact of Combined Oral Contraceptive Use Among Ovarian Cancer Patients in Addis Ababa, Ethiopia - A Cohort Study | PDF",1790084192,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b88ff04c846a1f35940478bc45d19b6.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14bca5e60c8b652a06f65007011a7b58.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f357cc6298d5477d31815f4b1218a49e.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19c95dca1d63bbbf45a9f1bf8ebc5e5a.webp",980,1306]